ArticleBMJ open2025
Perioperative intranasal dexmedetomidine for the prevention of chronic postsurgical pain following thoracoscopic surgery: protocol for a multicentre randomised controlled trial.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06849466 (Effect of Perioperative Dexmedetomidine Sleep Promotion Management on Chronic Post-Surgical Pain), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Perioperative Dexmedetomidine Sleep Promotion Management on Chronic Post-Surgical Pain: A Randomized Controlled Trial
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic postsurgical pain (CPSP) is common among patients undergoing thoracic surgery, with an incidence of up to 43.99% even with video-assisted thoracoscopic surgery (VATS). CPSP is associated with prolonged opioid use and significantly reduced quality of life. Currently, there are no consistently effective preventive measures. Poor perioperative sleep quality has been increasingly recognised as a key contributing factor to CPSP. Therefore, improving perioperative sleep quality is a potentially modifiable factor in the prevention of CPSP. Dexmedetomidine, an α2-adrenergic receptor agonist, has been shown to improve sleep quality in various patient populations. However, direct evidence supporting its role in reducing the incidence of CPSP is lacking. The aim of this multicentre randomised controlled trial is to investigate the efficacy of perioperative intranasal dexmedetomidine to optimise sleep and reduce the incidence of CPSP. METHODS AND ANALYSIS: This prospective, randomised controlled trial will enrol 364 patients undergoing elective VATS. Eligible patients who meet the inclusion and exclusion criteria will be randomly assigned to either the dexmedetomidine group or the control group. Patients in the dexmedetomidine group will receive perioperative intranasal dexmedetomidine spray, while those in the control group will receive an equivalent volume of intranasal normal saline. Assessments will be conducted at baseline, on postoperative days 1, 2 and 3, and at 1, 3 and 6 months after surgery. The primary outcome is CPSP at 3 months postoperatively. Secondary outcomes include sleep quality, emotional status, pain intensity and opioid consumption. ETHICS AND DISSEMINATION: The study protocol was approved by the Peking Union Medical College Hospital Institutional Review Board (Ethics Review Committee No. I-25PJ0337) on 7 February 2025. The trial was registered on ClinicalTrials.gov on 16 March 2025, in accordance with ICMJE guidelines. The results will be published in academic journals and disseminated at research conferences. TRIAL REGISTRATION NUMBER: NCT06849466.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.